Recent ucsdsom_biomarkerssymposium_2025 items

Evaluating Pediatric High-Sensitivity Troponin Thresholds and Testing Trends: A Multicenter Retrospective Cohort Study

Tue, 12 May 2026 00:00:00 +0000

Evaluating Pediatric High-Sensitivity Troponin Thresholds and Testing Trends: A Multicenter Retrospective Cohort Study

Alexander J F Thurston^1*, Eirik Å. Røys^2,3*, Ragnhild Røysland^4,5, Øyvind Skadberg⁶, Dorien M Kimenai⁷, Nicholas L Mills^7,8, Kristin M Aakre^2,3,9

¹Centre for Cardiovascular Science, The University of Edinburgh, Edinburgh, UK² Department of clinical science, University of Bergen, Bergen, Norway³ Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway⁴Multidisciplinary Laboratory Medicine and Medical Biochemistry, Division of Diagnostics and Technology, Akershus University Hospital, Lørenskog, Norway⁵Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway⁶Laboratory of Medical Biochemistry,...

Management of Uncomplicated Myocarditis in a Young Athlete

Tue, 12 May 2026 00:00:00 +0000

Management of Uncomplicated Myocarditis in a Young Athlete

Oscar Levine, Masihullah Barat, David Torres Barba, Ori Ben-Yehuda¹

¹UC San Diego Health

Background: A 17-year-old previously healthy male competitive soccer player presented to the emergency department with chest pain.

History: The patient woke up with sharp, pleuritic, substernal chest pain radiating to his right shoulder. One week prior, he had fever and myalgias, was diagnosed with influenza, and was treated with oseltamivir. He had no cardiac history, no family history of premature coronary artery disease, and denied alcohol, tobacco, or drug use.

Exams and images: Vital signs and physical exam were unremarkable. Lab work was notable for troponin T generation 5 initially at 169 ng/L and peaking at 493 ng/L (normal: <22 ng/L), with corresponding creatine kinase-myocardial...

Impact of Polygenic Risk Scoring on Lipid-Lowering Therapy in Primary Prevention for Coronary Artery Disease

Tue, 12 May 2026 00:00:00 +0000

Impact of Polygenic Risk Scoring on Lipid-Lowering Therapy in Primary Prevention for Coronary Artery Disease

Matthew Sangoi, Pranav Mellacheruvu, Nawaz Safdar, Rishitha Penmetsa, Skyler Burke, Maxwell Ambrosino, Nasser Monzer, Deepak Vedamurthy, Daniel Soffer, Douglas Jacoby

Corresponding Author: Rishitha Penmetsa, 9729889664, rishitha.penmetsa@utsouthwestern.edu

Pennsylvania Hospital of the University of Pennsylvania, Philadelphia, PA, United States

Perelman School of Medicine, Philadelphia, PA, United States

UT Southwestern School of Medicine, Dallas, TX, United States

Background: Polygenic risk scores (PRS) estimate inherited risk for coronary artery disease (CAD) by aggregating multiple genetic variants. Emerging data suggest PRS can enhance traditional risk models, particularly in younger or borderline-risk patients, before clinical risk factors develop. As validation across...

Contemporary Recurrent Pericarditis Management – Real-World Evidence of Limited Cardiac Magnetic Resonance Imaging Prior to Initiating Rilonacept

Tue, 12 May 2026 00:00:00 +0000

Contemporary Recurrent Pericarditis Management – Real-World Evidence of Limited Cardiac Magnetic Resonance Imaging Prior to Initiating Rilonacept

Brittany Weber, MD, PhD¹,Paul C. Cremer, MD², Michael S. Garshick, MD^3,4, Sushil A. Luis, MBBS, PhD⁵,Ajit Raisinghani, MD⁶, Vidhya Parameswaran, MPH⁷, Allison Curtis, PhD^7*, Allan L. Klein, MD⁸, John F. Paolini,MD, PhD⁷, on behalf of the RESONANCE Study Group.

Presenter: Corina Grancorvitz⁷

*Corresponding author:

¹Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women‘s Hospital, Harvard Medical School, Boston, MA, USA;

²Bluhm Cardiovascular Institute, Northwestern University Feinberg School...

Lipoprotein(a) and Oxidized Phospholipids in Cardiac Allograft Vasculopathy

Thu, 30 Apr 2026 00:00:00 +0000

Background/Synopsis:

Lipoprotein(a) [Lp(a)] is an inherited pro-atherogenic lipoprotein associated with cardiovascular diseases. Lp(a) acts as a carrier of oxidized phospholipids, which activate inflammatory response and promote formation of atherosclerotic plaques. The OxPL-apoB method quantifies the content of oxidized phospholipids on apolipoprotein B-100 containing particles, particularly Lp(a) and LDL-C. Cardiac allograft vasculopathy (CAV) is characterized by progressive coronary intimal thickening in heart allografts. This study aims to investigate the association of Lp(a) and OxPL-apoB with early CAV development in cardiac transplant (HTx) recipients.

Methods: A single-center, retrospective study analyzed 99 HTx recipients between 2015 to 2025 with measured Lp(a) and at least one post-HTx coronary angiogram with highly sensitive intravascular ultrasound (IVUS). We defined elevated Lp(a) as >50...